EGFR and non-small cell lung carcinoma: In recent phase III trials of the EGFR-TKI, gefitinib, demonstrated a significant superiority on progression-free survival (PFS) over standard chemotherapies as the first-line treatment for EGFR-mutated advanced non–small cell lung cancer (NSCLC) [4,5].